Ascendis Pharma A/S (NASDAQ:ASND) Lowered to Hold Rating by Wall Street Zen

Ascendis Pharma A/S (NASDAQ:ASND) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

A number of other equities research analysts have also weighed in on ASND. Barclays boosted their price objective on shares of Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Weiss Ratings upgraded Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a research note on Wednesday. Royal Bank Of Canada lifted their price target on Ascendis Pharma A/S from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Wells Fargo & Company dropped their price target on Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Finally, Oppenheimer reissued an “outperform” rating on shares of Ascendis Pharma A/S in a report on Tuesday, June 9th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of “Buy” and a consensus price target of $295.67.

Ascendis Pharma A/S Stock Up 0.5%

NASDAQ:ASND opened at $261.00 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. Ascendis Pharma A/S has a twelve month low of $160.86 and a twelve month high of $282.15. The company has a market cap of $16.28 billion, a PE ratio of 30.10 and a beta of 0.37. The company’s 50 day moving average is $242.89 and its two-hundred day moving average is $232.02.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The company had revenue of $285.45 million during the quarter, compared to analysts’ expectations of $362.47 million. Analysts anticipate that Ascendis Pharma A/S will post 4.63 EPS for the current year.

Insider Buying and Selling at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime bought 400 shares of Ascendis Pharma A/S stock in a transaction that occurred on Tuesday, May 26th. The stock was purchased at an average price of $237.80 per share, with a total value of $95,120.00. Following the completion of the acquisition, the director directly owned 400 shares in the company, valued at approximately $95,120. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $238.49, for a total transaction of $4,641,015.40. The disclosure for this sale is available in the SEC filing. 40.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ascendis Pharma A/S

Institutional investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP lifted its holdings in shares of Ascendis Pharma A/S by 114.8% in the 1st quarter. Seven Fleet Capital Management LP now owns 12,179 shares of the biotechnology company’s stock valued at $2,786,000 after buying an additional 6,509 shares during the period. Parallel Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 94.9% in the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after buying an additional 148 shares during the last quarter. Perceptive Advisors LLC grew its holdings in Ascendis Pharma A/S by 41.6% during the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock worth $350,282,000 after acquiring an additional 450,000 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Ascendis Pharma A/S by 34.0% during the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 69 shares during the period. Finally, Eagle Health Investments LP purchased a new position in Ascendis Pharma A/S during the first quarter valued at approximately $19,819,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.